Category Archives: Novartis Case

Inside Views: USTR’s Investigations On IP Rights Against India: Is There A Tenable Case?

Source: Ip-Watch On 14th October, the US Trade Representative (USTR) began the out-of-cycle review (OCR) of India’s intellectual property (IP) laws, the mandate which it gave itself in the 2014 Special 301 Report. Like several years in the past, the … Continue reading

Posted in Compulsory Licensing, Innovation, Novartis Case, Out of Cycle Review (OCR), Patents, TRIPS, US India BIT, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

Why did Modi agree to give away India’s patent sovereignty to Americans?

Source: First Post With the hype of his Madison Square Garden show overshadowing everything else, Prime Minister Narendra Modi’s US visit was dubbed as a great bilateral victory for India. As the popular consensus went, Modi wowed both the Indian … Continue reading

Posted in Innovation, IP Rights, IPR policy, Novartis Case, Patents, Right to Health, TRIPS flexibilities, US pressure on India | 1 Comment

The right prescription in the IPR debate

Source: Hindustan Times Sptember 29,2014 Prime Minister Narendra Modi is in the United States. As part of the agenda for the visit, both countries will unfold their wishlist for the other. Chief on the list will be the US Trade … Continue reading

Posted in Compulsory Licensing, Novartis Case, Right to Health | Tagged , , , | Leave a comment

Defending India’s patent law

Source: The Hindu 12 May 2014 No one can attack India’s well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) … Continue reading

Posted in Compulsory Licensing, Evergreening, Indian Patent Law, Novartis Case, Patent Injunction, US pressure on India | Leave a comment

A flimsy case against Indian pharma

Source: Business Line 10 March 2014 Trade tensions between the US and India are on the rise. Multiple trade organisations have asked the US Trade Representative to designate India a Priority Foreign Country in its annual review of countries that … Continue reading

Posted in Compulsory Licensing, Evergreening, Indian Patent Law, Novartis Case, Sec 3 (d), TRIPS, TRIPS flexibilities, US pressure on India | Leave a comment

How drug companies price patients out of survival

Source: Salon As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another health care battle rages in village clinics and corporate boardrooms. Behind the seductive commercials for breakthrough treatments, multinational brands … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, EU-India FTA, Evergreening, Generics, HIV/Aids, Indian Patent Law, IP Rights, IPR Enforcement, Medicine Patent Pool, NAFTA, Novartis Case, Patent examination system, Patents, Right to Health, Sec 3 (d), TPP, Trade Agreements, TRIPS, TRIPS flexibilities, Tuberculosis (TB), WHO, WTO | Tagged , | Leave a comment

SURPRISE! BIG PHARMA DON’T WANT DEVELOPING COUNTRIES HAVING ACCESS TO CHEAP MEDICINE

Source: http://www.vice.com Compared to a number of other nations, India has done an incredible job of keeping medicine cheap enough that its citizens can afford to buy whatever it is that they need. Most importantly, it avoids handing out patents … Continue reading

Posted in Compulsory Licensing, Evergreening, Indian Patent Law, Novartis Case, Sec 3 (d), TRIPS flexibilities | Leave a comment